Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|March 24, 2017
How Value-based Care Could Affect Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Grant E. Knowles, PharmD, vice president of Business Development at Ardon Health, discusses the potential impact of value-based care on specialty pharmacy.
Advertisement
Grant E. Knowles, PharmD, vice president of Business Development at Ardon Health, discusses the potential impact of value-based care on specialty pharmacy.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
5